Immunotherapy Resistance in Non-small-cell Lung Cancer: From Mechanism to Clinical Strategies

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Apr 24

PMID 37090727

Authors

Suna Zhou

Haihua Yang

Affiliations

Soon will be listed here.

Abstract

The high primary resistance incidence and unavoidable secondary resistance are the major clinical obstacle to lasting long-term benefits in Non-small-cell lung cancer (NSCLC) patients treated with immunotherapy. The mechanisms of immunotherapy resistance in NSCLC are complex, mainly involving tumor cells and tumor microenvironment (TME) infiltrating immune cells, including TAMs, B cells, NK cells, and T cells. The selection of clinical strategies for NSCLC progression after immunotherapy resistance should depend on the progressive mode. The progression pattern of NSCLC patients after immunotherapy resistance can be divided into oligo-progression and systemic/multiple progression, which should be considered for further treatment selection. In the future, it needs to explore how to optimize the combined therapy and explore strategies to reprogram infiltrating immune cells under various genetic backgrounds of tumor cells and timely reshape TME during antitumor treatments.

Citing Articles

CD73/adenosine dynamics in treatment-induced pneumonitis: balancing efficacy with risks of adverse events in combined radio-immunotherapies.

Gockeln L, Wirsdorfer F, Jendrossek V Front Cell Dev Biol. 2025; 12:1471072.

PMID: 39872847 PMC: 11769960. DOI: 10.3389/fcell.2024.1471072.

Treatment Options for Advanced Non-Small Cell Lung Cancer After Failure of Previous Immune Checkpoint Inhibitors and Chemotherapy: Meta-Analysis of Five Randomized Controlled Trials.

Messori A, Ossato A, Gasperoni L, Del Bono L, Inno A, Damuzzo V Curr Oncol. 2025; 32(1.

PMID: 39851962 PMC: 11763427. DOI: 10.3390/curroncol32010046.

Immune Checkpoint Blockade Combined with AbnobaViscum Therapy Is Linked to Improved Survival in Advanced or Metastatic Non-Small-Cell Lung Cancer Patients: A Registry Study in Accordance with the ESMO Guidance for Reporting Real-World Evidence.

Schad F, Thronicke A, Hofheinz R, Klein R, Grabowski P, Oei S Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770555 PMC: 11677823. DOI: 10.3390/ph17121713.

Addressing the unmet need in NSCLC progression with advances in second-line therapeutics.

Wang K, Leyba A, Hsu R Explor Target Antitumor Ther. 2025; 5(6):1297-1320.

PMID: 39759220 PMC: 11700623. DOI: 10.37349/etat.2024.00277.

Biomarkers for immunotherapy resistance in non-small cell lung cancer.

Rother C, John T, Wong A Front Oncol. 2025; 14:1489977.

PMID: 39749035 PMC: 11693593. DOI: 10.3389/fonc.2024.1489977.

References

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J . Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2016; 389(10066):255-265. PMC: 6886121. DOI: 10.1016/S0140-6736(16)32517-X. View

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

Kato Y, Tabata K, Kimura T, Yachie-Kinoshita A, Ozawa Y, Yamada K . Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One. 2019; 14(2):e0212513. PMC: 6392299. DOI: 10.1371/journal.pone.0212513. View

Sumimoto H, Takano A, Teramoto K, Daigo Y . RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers. PLoS One. 2016; 11(11):e0166626. PMC: 5112979. DOI: 10.1371/journal.pone.0166626. View

Rheinheimer S, Heussel C, Mayer P, Gaissmaier L, Bozorgmehr F, Winter H . Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors. Cancers (Basel). 2020; 12(4). PMC: 7226015. DOI: 10.3390/cancers12041046. View

Zhou S, Xie J, Huang Z, Deng L, Wu L, Yu J . Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges. Cancer Lett. 2021; 502:166-179. DOI: 10.1016/j.canlet.2020.12.043. View

Herbst R, Garon E, Kim D, Cho B, Perez-Gracia J, Han J . Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study. J Clin Oncol. 2020; 38(14):1580-1590. DOI: 10.1200/JCO.19.02446. View

McGranahan N, Rosenthal R, Hiley C, Rowan A, Watkins T, Wilson G . Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017; 171(6):1259-1271.e11. PMC: 5720478. DOI: 10.1016/j.cell.2017.10.001. View

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot A, Mezquita L . Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019; 30(8):1321-1328. PMC: 7389252. DOI: 10.1093/annonc/mdz167. View

10.

Sotelo M, Cabezas-Camarero S, Riquelme A, Bueno C . Long-term survival of a patient with programmed death ligand 1-negative lung adenocarcinoma and oligoprogressive disease treated with nivolumab and stereotactic body radiation therapy. J Cancer Res Ther. 2020; 16(4):941-945. DOI: 10.4103/jcrt.JCRT_81_19. View

11.

Backman M, La Fleur L, Kurppa P, Djureinovic D, Elfving H, Brunnstrom H . Infiltration of NK and plasma cells is associated with a distinct immune subset in non-small cell lung cancer. J Pathol. 2021; 255(3):243-256. DOI: 10.1002/path.5772. View

12.

Mildner F, Sopper S, Amann A, Pircher A, Pall G, Kock S . Systematic review: Soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC). Crit Rev Oncol Hematol. 2020; 153:102948. DOI: 10.1016/j.critrevonc.2020.102948. View

13.

Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R . Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discov. 2017; 7(12):1420-1435. PMC: 5718941. DOI: 10.1158/2159-8290.CD-17-0593. View

14.

Antonia S, Borghaei H, Ramalingam S, Horn L, de Castro Carpeno J, Pluzanski A . Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol. 2019; 20(10):1395-1408. PMC: 7193685. DOI: 10.1016/S1470-2045(19)30407-3. View

15.

Yang J, Gadgeel S, Sequist L, Wu C, Papadimitrakopoulou V, Su W . Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. J Thorac Oncol. 2018; 14(3):553-559. DOI: 10.1016/j.jtho.2018.11.028. View

16.

Poma A, Bruno R, Pietrini I, Ali G, Pasquini G, Proietti A . Biomarkers and Gene Signatures to Predict Durable Response to Pembrolizumab in Non-Small Cell Lung Cancer. Cancers (Basel). 2021; 13(15). PMC: 8345106. DOI: 10.3390/cancers13153828. View

17.

Lastwika K, Wilson 3rd W, Li Q, Norris J, Xu H, Ghazarian S . Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. Cancer Res. 2015; 76(2):227-38. DOI: 10.1158/0008-5472.CAN-14-3362. View

18.

Heo J, Yoo S, Suh K, Kim S, Kim Y, Ock C . Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients. Sci Rep. 2021; 11(1):2514. PMC: 7844257. DOI: 10.1038/s41598-021-81666-x. View

19.

Morimoto Y, Kishida T, Kotani S, Takayama K, Mazda O . Interferon-β signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells. Biochem Biophys Res Commun. 2018; 507(1-4):330-336. DOI: 10.1016/j.bbrc.2018.11.035. View

20.

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman D . IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017; 127(8):2930-2940. PMC: 5531419. DOI: 10.1172/JCI91190. View